CapitolRadar tracks every publicly disclosed ARTV trade by US congress members and corporate insiders: 0 disclosed trades (0 buys, 0 sells) by 0 tracked traders. Updated daily from official filings.
Want a ping when Congress buys ARTV? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Artiva Biotherapeutics, Inc. (ARTV) — Healthcare · Biotechnology, market cap about $0.3B.
Cluster watch: 12 distinct tracked traders disclosed buying ARTV in the last 45 days: MOORE ALISON (director), Stoppel Laura (director), Sorg Elaine K. (director), HOUGEN ELIZABETH L (director), DANIELS BRIAN (director), Baker Daniel G. (director).
CapitolRadar signal history
NEW PICK 2026-09-15
Artiva CEO and director Fred Aslan bought about $1.62 million of ARTV stock, while 11 other tracked buyers also purchased shares within 45 days. The trade fell short mainly because Aslan has no verified performance history versus SPY, so his large purchase remains an unproven signal. A documented record showing that his prior buys consistently outperformed SPY would have strengthened the case enough to change the verdict.
NEW PICK 2026-09-11
Artiva Biotherapeutics officer Christopher Horan reportedly bought about $1.29 million of ARTV stock, while several other insiders also bought recently. The panel passed mainly because the reported 2026 trade and disclosure dates are future-dated, making the signal hard to verify despite its size. A confirmed SEC Form 4 showing the correct dates, share count, and purchase price could have changed the verdict; Horan also has no verified trading record.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis …
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.